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1. Introduction  
Diabetic retinopathy (DR) is a leading cause of visual loss and blindness in adults in 
developed and developing countries (Friedman et al., 2011). Clinical trials have shown that 
intensive glycemic control reduces the incidence and progression of DR (Reichard et al., 
1993; Stratton et al., 2001; DCCT, 2002 ). Other metabolic factors also affect the progression 
and development of DR. The UK Prospective Diabetes Study Group reported that tight 
blood pressure control is effective for reducing the incidence of DR (UK Prospective 
Diabetes Study Group, 1998a, 1998b). The EUCLID study group reported that inhibitors of 
angiotensin-converting enzyme drugs decreased the progression of retinopathy in patients 
without hypertension who had type 1 diabetes with little or no nephropathy (Chaturvedi et 
al., 1998). Lipid-lowering therapy with fenofibrate also might reduce the progression of DR 
(Chew et al., 2010; Keech et al., 2007). Among the metabolic factors, although glycemic 
control seems to be the most important, achieving acceptable glucose homeostasis is 
difficult, even when patients are highly compliant. Furthermore, DR continues to develop 
and progress even in patients who are treated intensively to achieve better glycemic control. 
Therefore, it is important to find medical options other than glycemic control to prevent 
diabetic ocular complications. The metabolic changes that accompany hyperglycemia, such 
as activation of the polyol pathway (Gabbay, 1973; Lorenzi, 2007; Robison et al., 1988; 1989), 
activation of protein kinase C (PKC) (Frank, 2002; Liang et al., 2005; Shiba et al., 1993), 
increased oxidative stress (Gurler et al., 2000; Jennings et al., 1991; Pan et al., 2008; Pinto et 
al., 2007), leukocyte adhesion to the endothelial cells (McLeod et al., 1995; Miyamoto et al., 
1996; Schroder et al., 1991), and accumulation of advanced glycation end products (AGEs) 
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(Chibber et al., 1997; Hirata et al., 1997; Kakehashi et al., 2008), are related to the 
development and progression of diabetic ocular complications. In particular, the polyol 
pathway is correlated strongly with oxidative stress, activation of PKC, and accumulation of 
AGEs that lead to induction of vascular endothelial growth factor (VEGF). A key enzyme in 
the polyol pathway, aldose reductase (AR), is found in the retina and lens (Akagi et al., 1983; 
Kern & Engerman, 1981). AR inhibitors (ARIs) slowed thickening of the basement 
membrane of the retinal capillaries and progression of diabetic cataract in experimental 
studies (Hu et al., 1983; Robison et al., 1983). Thus, the polyol pathway might be the most 
attractive target for adjunctive treatment to prevent development of diabetic ocular 
complications. Based on favorable observations from experimental studies using ARIs 
(Obrosova et al., 2005; Okuda et al., 1985; Robinson et al., 1996; Sun et al., 2006; Yeh et al., 
1986), a clinical trial of the ARI, sorbinil, was conducted in 1990, but this drug did not affect 
the development of DR, and enthusiasm for the clinical application of ARIs waned. To test 
drugs to treat DR, good animal models of DR would be useful. In this context, the 
spontaneously diabetic Torii (SDT) rat, a newly established non-obese type 2 diabetes model 
rat, seems especially appropriate, since it shows advanced DR resembling that in humans 
(Kakehashi et al., 2006; Kakehashi, 2011a, b; Shinohara et al., 2000). A recent study showed a 
strong preventative effect of ARIs on the development of DR in this animal model 
(Kakehashi et al., 2011).  
In this chapter, we discuss several studies of medical treatment to prevent DR including our 
previous and ongoing studies using SDT rats. Among the various medical treatments, we 
have focused on the ARIs, because we believe that they are the most potent and safest of the 
potential treatments. 
2. ARIs 
Many experimental studies of ARIs (Obrosova et al., 2005; Okuda et al., 1985; Robinson et 
al., 1996; Sun et al., 2006; Yeh et al., 1986) have reported favorable results, with the exception 
of a clinical trial of sorbinil as mentioned previously.  
However, our recent study on the effects of the ARI, fidarestat (SNK-860; Sanwa Kagaku 
Kenkyusho, Nagoya, Japan), in SDT rats showed that the drug strongly inhibited the 
development of DR (Kakehashi et al., 2011). We evaluated four rat groups: untreated, low- 
and high-dose (8 and 32 mg/kg/day) fidarestat-treated SDT rats, and nondiabetic control 
Sprague-Dawley (SD) rats. We evaluated the DR and measured the retinal sorbitol and 
reduced glutathione (GSH), VEGF in the ocular fluid, and urinary 8-hydroxy-2’-
deoxyguanosine (8-OHdG). Compared with the untreated the incidence of DR was 
significantly lower in the low- and high-dose fidarestat groups group. Compared with the 
untreated group, the retinal sorbitol levels were lower in the control and low- and high-dose 
groups; the retinal GSH levels were higher in the control and the low- and high-dose 
groups; the VEGF levels were lower in the control and low- and high-dose groups; and the 
8-OHdG levels were lower in the control and low- and high-dose groups. The results 
indicated that fidarestat prevents DR in SDT rats by suppressing oxidative stress and 
sorbitol production.  
Based on these findings, we evaluated the recently developed ARI, ranirestat (AS-3201, 
Dainippon Sumitomo Pharmaceutical Co., Ltd., Osaka, Japan) for treating DR in SDT rats. 
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Male SDT rats and SD rats were obtained from CLEA, Inc., Tokyo, Japan. All SDT rats were 
confirmed to be diabetic based on a non-fasting blood glucose concentration exceeding 19.4 
mmol/L. All rats were fed standard rat chow (CRF-1, Oriental Yeast, Inc., Tokyo, Japan) with 
or without ARI. Epalrestat (Kinedak, Ono Pharmaceutical Co., Ltd., Osaka, Japan), an ARI that 
is commercially available in Japan, was used as the positive control. The ranirestat-treated rats 
received the drug once daily; the epalrestat-treated rats were fed chow containing epalrestat at 
the onset of diabetes; and the SD rats and untreated SDT rats were fed chow without an ARI.  
The animals were divided into six groups: normal SD rats (n=8), untreated SDT rats (n=9), 
ranirestat-treated SDT rats (0.1 mg/kg/day for 40 weeks, n=7; 1.0 mg/kg/day for 40 weeks, 
n=8; 10.0 mg/kg/day for 40 weeks, n=7), and epalrestat-treated SDT rats (100 mg/kg/day 
for 40 weeks) (n=8). 
The body weight, blood glucose, and glycosylated hemoglobin (HbA1c) were measured 
once monthly. Blood samples were collected from the tail vein of the non-fasting rats to 
measure the plasma glucose and glycosylated hemoglobin levels. The body weight was 
greater in the SD than that in SDT rats with or without treatment (p<0.01). The mean plasma 
glucose levels and HbA1c levels in the SD rats were significantly (p<0.01) lower than in the 
SDT rats with or without treatment. However, there were no significant differences in the 
blood glucose levels and HbA1c levels between the treated and untreated SDT rats, 
indicating that an ARI did not affect the glycemic control. Therefore, we did not have to 
consider any effect of glycemia in interpreting results. 
Fluorescein-dextran microscopy was performed after intracardiac injection of fluorescein-
dextran (fluorescein isothiocyanate dextran, Sigma, St. Louis, MO, USA), using a 
modification of the method of D'Amato et al. (1993). With the animals under deep 
anesthesia induced by intraperitoneal injection of pentobarbital sodium (25 mg/kg body 
weight, Nembutal, Dainihonseiyaku, Osaka, Japan), 1 ml of phosphate buffered saline 
containing 50 mg of fluorescein dextran was injected into the left ventricle of each animal. 
After 5 minutes, the eyes were enucleated for fluorescein microscopy. The retinas were 
peeled from the eyecups, and the entire retinas were flat-mounted on a slide glass without 
fixation. A drop of aqueous mounting medium (Crystal/Mount, Biomeda Corp., Foster 
City, CA, USA) was applied over the retinas and allowed to dry. The flat-mounted retinas 
were examined by fluorescence microscopy (Nikon SMZ1500 with P-FLA fluorescence 
attachment, Nikon, Tokyo, Japan). As we reported previously (Kakehashi et al., 2006), DR 
was diagnosed when extensive fluorescein leakage was seen around the optic disc, and we 
classified the DR into three stages: no retinopathy (no dye leakage), mild retinopathy (mild 
dye leakage around the optic disc), and severe retinopathy (extensive dye leakage 
throughout the entire retina) (Fig. 1). 
With the animals under deep anesthesia induced by intraperitoneal injection of 
pentobarbital sodium, the eyes were enucleated for conventional histopathologic studies 
and placed in a fixative (Superfix KY-500, Kurabo, Tokyo, Japan) to avoid iatrogenic retinal 
detachment. The fixed eyes were washed in 0.1% mol/L cacodylate buffer and embedded in 
paraffin. The paraffin block was cut into 4-µm sections and stained with hematoxylin and 
eosin for conventional histopathologic examination. As reported previously (Kakehashi et 
al., 2006), DR was diagnosed when large retinal folds mimicking tractional retinal 
detachment around the optic disc were observed.  
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Retinopathy (-) Retinopathy (+) Retinopathy (++) 
Fig. 1. Classification of diabetic retinopathy. Retinopathy (-), no dye leakage; retinopathy(+), 
mild dye leakage around the optic disc; retinopathy (++), extensive dye leakage throughout 
the retina. 
Compared with controls (7/9 eyes), DR did not develop in any ranirestat-treated groups (0.1 
mg/kg/day; 1.0 mg/kg/day; 10.0 mg/kg/day for 40 weeks) (0/7, 0/8, 0/7 eyes, p<0.01, 
chi-square test). Mild DR developed in the epalrestat-treated group (100 mg/kg/day for 40 
weeks) (2/8 eyes; p=0.09 by the chi-square test). Epalrestat did not prevent development of 
DR in SDT rats. The incidence of DR was significantly (p<0.01) lower in the ranirestat-
treated groups compared with the untreated group. 
Immunohistochemical procedures were based on the standard avidin-biotin horseradish 
peroxidase method using the appropriate antibody and developed with AEC Substrate 
Chromogen (DakoCytomation, Carpinteria, CA, USA). VEGF was immunostained with a 
monoclonal antibody for human VEGF (1:25 dilution, Immuno-Biological Laboratories Co., 
Ltd., Fujioka, Japan). Carboxymethyl-lysine (CML) was immunostained with a monoclonal 
antibody for human AGEs (1:50 dilution for CML, Trans Genic Inc., Kumamoto, Japan). 
Bovine serum was used as the primary antibody for the negative control. The 
immunostaining grades were divided into three groups: minimal (-), moderate (+), and 
severe (++). Minimal staining was characterized by almost no retinal staining, moderate 
staining by light red retinal staining, and severe staining by intense dark red retinal staining. 
Fig. 2 shows immunostaining for CML and VEGF. Immunostaining for CML was very 
strong in the untreated eye (upper left) compared with minimal staining in the ranirestat-
treated (10 mg/kg/day for 40 weeks) eye (lower left). Immunostaining for VEGF was 
moderate in the untreated eye (upper right) compared with minimal staining in the 
ranirestat-treated eye (lower right). 
Strong immunostaining for CML was seen in eight of nine eyes of the untreated SDT rats. The 
staining significantly (p<0.05) decreased to the moderate level in the eyes treated with 1.0 
mg/kg/day and 10.0 mg/kg/day of ranirestat, except for those treated with 0.1 mg/kg/day 
of ranirestat (p=0.111). Epalrestat did not have a significant (p=0.241) effect. Moderate 
immunostaining for VEGF was seen in eight of nine eyes in the untreated SDT rats, and this 
decreased significantly (p<0.05) to minimal staining in the rats treated with 1.0 mg/kg/day 
and 10.0 mg/kg/day of ranirestat, but not in those treated with the 0.1 mg/kg/day dose of 
ranirestat (p=0.117). Epalrestat did not have a significant effect (p=0.247). 
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Fig. 2. Immunostaining for CML and VEGF. Immunostaining for CML shows strong 
staining in the untreated eye (upper left) compared with minimal staining in the ranirestat-
treated eye (lower left). Immunostaining for VEGF shows moderate staining in the 
untreated eye (upper right) compared with minimal staining in the ranirestat-treated eye 
(lower right).   
The retinal sorbitol and fructose levels were measured. ARI activity was determined after 
the liquid chromatography-tandem mass spectrometry method was performed. Briefly, rats 
were anesthetized with sodium pentobarbital (50 mg/kg, intra peritoneally; Abbott, Abbott 
Park, IL, USA), and the retinas were removed, promptly cooled with liquid nitrogen, and 
stored at −50°C. The samples for the sorbitol and fructose assay were prepared by protein 
precipitation followed by a solid-phase extraction procedure. The API 4000 Mass 
Spectrometer (AB SCIEX, Tokyo, Japan) was operated in the selected-reaction monitoring 
mode under optimized conditions to detect sorbitol- or fructose-negative ions formed by 
atmospheric pressure chemical ionization. At 15 weeks, the sorbitol levels in the retina of the 
SDT rats treated with ranirestat (10.0 mg/kg/day) were lower than in the untreated eyes. 
Eparlestat did not affect the retinal sorbitol levels. However, there were no significant 
differences in the sorbitol levels among the treated and untreated SDT rats at 40 weeks. 
Retinal fructose levels were lower at 15 weeks in SDT rats treated with ranirestat (10.0 
mg/kg/day) than those that were untreated. Eparlestat did not affect the retinal fructose 
levels. At 40 weeks, there were no significant differences in the retinal fructose levels among 
the rat groups. 
3. Other options for prophylactic medical treatment of DR 
3.1 PKC β inhibitor 
Liang and coworkers (2005) reported amelioration of vascular dysfunction in diabetic rats 
using an oral PKC ǃ inhibitor. Those authors later reported that VEGF increases intraocular 
vascular permeability through activation of PKC in vivo and suggested that oral 
pharmacologic therapies involving PKC ǃ-isoform-selective inhibitors might be effective for 
treating DR (Aiello et al., 1997). Based on their report, the oral PKC ǃ inhibitor, 
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ruboxistaurin (RBX) (LY333531, Eli Lilly and Co., Indianapolis, IN), administered to patients 
with diabetes with no or mild DR, ameliorated diabetes-induced retinal circulation time 
abnormalities (Aiello et al., 2006). Another multicenter, double-masked, randomized, 
placebo-controlled study in patients with diabetes with moderate to very severe 
nonproliferative diabetic retinopathy showed that RBX was well tolerated and reduced the 
risk of visual loss but did not prevent DR progression (PKC-DRS Study Group, 2005). 
We evaluated the effect of our PKC ǃ inhibitor (JTT-010, Takatsuki, Japan) on the 
development of diabetic ocular complications in SDT rats. The rats had delayed oscillatory 
potentials on electroretinography, but DR developed eventually. We concluded that PKC ǃ 
inhibitors may require concurrent administration of antihyperglycemic drugs to achieve 
maximal therapeutic effects on DR (Sasase et al., 2009). 
3.2 Anti-AGE agents 
Previous studies have suggested the concept of “metabolic memory” associated with 
accumulation of AGEs as DR develops (Chibber et al., 1997; Genuth et al., 2005; Hammes et 
al., 1999). Another anti-AGE agent, pyridoxamine, also prevented development of DR (Stitt 
et al., 2002). However, clinical trials of anti-AGE agents for the treatment of DR have not yet 
been conducted. 
Based on those reports, we evaluated the effects of oral aminoguanidine and pyridoxamine 
on the development of cataract and DR in SDT rats (Toyoda et al., 2011) and reported that 
aminoguanidine prevented accumulation of CML and resulted in almost complete 
inhibition of DR, but pyridoxamine did not prevent DR. Aminoguanidine seems to be a 
stronger inhibitor of DR than pyridoxamine.  
3.3 Anti-leukocyte adhesion agents 
Leukocyte adhesion to the diabetic retinal vasculature is thought to be the critical early 
event in the pathogenesis of DR, resulting in breakdown of the blood-retinal barrier and in 
capillary nonperfusion (Gurler et al., 2000; Hu et al., 1983). Adamis and coworkers (1994) 
reported that the antileukocyte adhesion agents, anti-intercellular adhesion molecule-1 
antibody (Miyamoto et al., 1999) and anti-CD 18 antibody (Barouch et al., 2000), were useful 
for treating experimental DR. They also showed an antileukocyte adhesion effect using a 
PKC ǃ inhibitor (Nonaka et al., 2000) and receptor for the AGEs (Kaji et al., 2007). Nagai et 
al. (2007) reported an inhibitory effect of an angiotensin II type 1 receptor blocker on retinal 
leukostasis in diabetic mice. 
We tested several commercially available antileukocyte adhesion agents in diabetic rats. We 
first evaluated the effectiveness of the sulphonylurea gliclazide for decreasing the adhesion 
of neutrophils to endothelial cells and leukocyte entrapment in the retinal microcirculation 
of streptozotocin (STZ)-induced diabetic rats. We showed that gliclazide attenuated retinal 
leukostasis irrespective of hyperglycemia in diabetic rats, whereas another sulphonylurea, 
glibenclamide, did not. This indicated that gliclazide, among the sulphonylurea drugs, 
might be selectively beneficial for preventing development of DR (Kinoshita et al., 2002). We 
also evaluated the effectiveness of topical nipradilol, a topical antiglaucoma ǂǃ-blocker and 
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nitric oxide donor, on retinal microvascular leukocyte adhesion in diabetic rats. Topical 
nipradilol significantly reduced retinal leukostasis in the retinal microcirculation of STZ-
induced diabetic rats, and we think that nipradilol may be a prophylactic agent that can 
inhibit development of early DR through its nitric oxide donor effects on the 
microcirculation. We believe that most antileukocyte adhesion agents can slow progression 
of DR but do not inhibit it completely. Good glycemic control or other additional medical 
treatments are needed to achieve a maximal effect on DR.  
3.4 Anti-VEGF agents 
Since the VEGF levels increase as DR progresses (Adamis et al., 1994; Aiello et al., 1994; 
Amin et al., 1997; Lutty et al., 1996), VEGF is very important in the development and 
progression of DR. VEGF is also a vascular permeability factor and plays an important role 
in the development of diabetic macular edema (DME) (Mathews et al., 1997). Based on these 
observations, several anti-VEGF agents such as an anti-VEGF antibody (Adamis et al., 1996), 
soluble VEGF-receptor chimeric proteins (Aiello et al., 1995), and antisense 
phosphorothioate oligodeoxynucleotides against VEGF (Robinson et al., 1996) have been 
tested in an animal model of retinal neovascularization mimicking DR. The results were 
very promising. Based on these favorable results in animal studies, several clinical studies 
have been undertaken to evaluate treatment of DME using an anti-VEGF antibody. The 
RESOLVE Study evaluated the safety and efficacy of intravitreal ranibizumab (Lucentis, 
Genentech, Inc., South San Francisco, CA) for treating patients with DME (Massin et al., 
2010). Ranibizumab is a fully humanized monoclonal antibody fragment, which binds to 
multiple variants of VEGF-A, and is approved to treat age-related macular degeneration. 
The results indicated that intravitreal ranibizumab improves visual acuity and reduces 
macular thickness in DME. The Diabetic Retinopathy Clinical Research Network (DRCR.net) 
is evaluating and comparing several medical treatments for DME. The DRCR.net is a 
collaborative network formed in September 2002 that is dedicated to facilitating multicenter 
clinical studies of DR, DME, and associated conditions. Currently, there are more than 109 
participating sites with over 320 physicians throughout the United States 
(http://drcrnet.jaeb.org/). The DRCR.net reported that intravitreal ranibizumab combined 
with laser treatment is more effective than laser treatment with or without triamcinolone. 
The anti-VEGF agents inhibit VEGF and increase capillary permeability. Macular edema is 
resolved by blocking increased capillary permeability. However, a drawback of the anti-
VEGF agents is that they do not have long-term efficacy, so repeated injections are usually 
required. Moreover, a 2% prevalence of endophthalmitis over 12 months in the RESOLVE 
Study is worrisome. To minimize the number of intravitreal injections, gene therapy using a 
safe virus vector, such as an adeno-associated virus (Ideno et al., 2007), may be a future 
option for treating DME.  
4. Comments 
Good glycemic control is the most important factor for preventing the development and 
progression of diabetic ocular complications. However, it is also difficult to obtain good 
glycemic control in many clinical cases. In this chapter, we discussed several additional 
medical therapeutic options for diabetic ocular complications. PKC ǃ inhibitors and 
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antileukocyte adhesion agents might help prevent DR, but neither was sufficient without 
good concurrent glycemic control or other additional medical treatments. Anti-VEGF agents 
have a strong therapeutic effect in DME; however, they do not have long-term efficacy and 
the possibility of complications, such as endophthalmitis, associated with injection of anti-
VEGF agents into the vitreous is a concern. Thus, anti-VEGF agents do not seem to be safe 
therapeutic options for preventing diabetic ocular complications. Oral anti-AGE agents 
seem to be good prophylactic medical treatments for DR in experimental animal studies. 
Clinical trials of oral anti-AGE agents for treating DR are worthwhile. Among the several 
prophylactic medical treatments for DR, we focused on the ARIs in this chapter. Epalrestat, 
which is commercially available in Japan, has been widely used to treat diabetic neuropathy. 
Although the effect of eparlestat on DR has not been clearly recognized in a clinical trial, the 
safety and clinical effects of long-term oral administration of the drug for treating diabetic 
neuropathy have been established. Thus, we believe that our findings suggest the potential 
therapeutic usefulness of a new ARI, ranirestat, for preventing DR. Importantly, it appears 
that ranirestat might prevent DR even without strict glycemic control. We look forward to 
the development and evaluation of new ARIs with minimal side effects for use in future 
clinical studies to prevent DR. 
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